Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluzopalil + Apatinib maintenance in recurrent ovarian cancer
NCT06188455Phase 3Not yet recruiting
- Sponsor
- First Affiliated Hospital of Xiamen University
- Start
- Dec 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of fluzoparib, Rivoceranib in ovarian cancer, sponsored by First Affiliated Hospital of Xiamen University. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
fluzoparibRivoceranib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT06188455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06188455.